Trial Profile

A Phase I/II COVID clinical trial of RAGE fusion protein

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 17 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RAGE fusion protein Galactica Pharmaceuticals (Primary)
Indications COVID 2019 infections
Focus Therapeutic Use
Sponsors Galactica Pharmaceuticals

Most Recent Events

17 Oct 2023 New trial record
11 Oct 2023 According to a Galactica Pharmaceuticals media release, If the expected endpoint is met, company expects to seek Emergency Use Authorization (EUA) from the United States Food and Drug Administration to quickly make the drug available to hospitalized COVID-19 patients.
11 Oct 2023 According to a Galactica Pharmaceuticals media release, company is looking forward to advancing RAGE investigational drug into a Phase I/II COVID clinical trial in the coming months.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com